5 Key Takeaways

• 1

  The CREST trial shows bioreinforced cyclodialysis significantly reduces intraocular pressure (IOP) and medication use in primary open-angle glaucoma patients.

• 2

  The bioreinforced cyclodialysis procedure utilizes the CycloPen system to create a cleft enhancing uveoscleral outflow during cataract surgery.

• 3

  At 24 months, mean medicated IOP decreased from 19.5 mmHg to 14.6 mmHg, with a reduction in IOP-lowering medications from 1.61 to 0.70.

• 4

  The CycloPen device uses biocompatible allograft tissue to maintain the drainage pathway, minimizing risks associated with previous synthetic devices.

• 5

  The bioreinforced cyclodialysis procedure offers a low learning curve for surgeons familiar with the CyPass device, enhancing surgical options.